Fewer approvals in 2022 from cautious FDA

After approving an average of 51 drugs per year since 2017, there were only 37 FDA approvals in 2022. It is speculated that the authority has taken a somewhat more cautious stance after the controversies surrounding Biogen’s Alzheimer’s drug Aduhelm. BioStock has taken a closer look at some of last year’s approvals and also at what the regulatory pipeline looks like for the first quarter of 2023.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/01/fewer-approvals-in-2022-from-cautious-fda/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se